Yingming Zhu
Shandong University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yingming Zhu.
Oncotarget | 2016
Yingming Zhu; Minghuan Li; Dianbin Mu; Li Kong; Jianbo Zhang; Fen Zhao; Zhenxiang Li; Xuemei Liu; Cong Bo; Jinming Yu
Data describing relationships between the tumor immune microenvironment and patient outcome are limited for esophageal squamous cell cancer (ESCC). The present study investigated the prognostic values of programmed death-ligand 1 (PD-L1) expression and CD8+ or forkhead box protein 3+ (FOXP3+) tumor-infiltrating lymphocytes (TILs) in 133 pathological T3N0M0 stage ESCC patients who underwent radical resection without neoadjuvant or adjuvant therapy. CD8+ and FOXP3+ TIL densities as well as PD-L1 levels in tumor cells and lymphocytes, were assessed through immunohistochemical staining. Patient survival was not associated with CD8+ or FOXP3+ TILs alone, but PD-L1 expression and the CD8+/FOXP3+ ratio were independent predictors of both disease-free and overall survival. PD-L1 expression correlated with age (p = 0.029), tumor length (p < 0.001), tumor differentiation status (p = 0.002) and reduced intratumoral CD8+ TIL density (p < 0.001). Our results suggest pT3N0M0 ESCC clinical outcomes correlate with CD8+ and FOXP3+ TIL densities and PD-L1 levels. Moreover, an intrinsic mechanism for induction of PD-L1 overexpression may be occurring during early tumor oncogenesis. This information may be useful for stratifying patients and guide the application of checkpoint blockade therapy in ESCC.
OncoTargets and Therapy | 2017
Xuemei Liu; M. Li; Fen Zhao; Yingming Zhu; Yijun Luo; Li Kong; Hui Zhu; Yan Zhang; Fang Shi; Jinming Yu
Background The lymphocyte–monocyte ratio (LMR), a simple biomarker that can reflect the antitumor immune response of the host, has been associated with patient prognosis in several solid tumors. The aim of this study was to evaluate whether LMR can predict clinical tumor response and prognosis in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received definitive chemoradiotherapy (CRT). Patients and methods A total of 162 advanced ESCC patients treated at our institution between January 2012 and December 2013 were retrospectively recruited for analysis. Patients were treated with a platinum-based bimodal cytotoxic drug chemotherapy and concurrent radiation therapy. The LMR was calculated from blood counts in samples collected prior to treatment initiation. The predictive value of LMR for clinical tumor response and prognosis was examined. Results The LMR before CRT was significantly higher in 48 patients who achieved clinical complete response (CR) compared to that in patients who did not achieve clinical CR (4.89±1.17 vs 3.87±1.29, P<0.001). Compared to their matched counterparts, patients in the high LMR group (LMR >4.02) showed a good clinical tumor response (P<0.05). A significant independent association between a high pretreatment LMR and better outcomes was identified in a multivariate analysis for progression-free survival (PFS; hazard ratio [HR]=2.17; P<0.001) and overall survival (OS; HR=2.02; P=0.002). Conclusion In ESCC patients, a high LMR before treatment, which indicates a robust host immune system, is associated with both a good clinical tumor response after definitive CRT and favorable prognosis.
Cancer management and research | 2018
Yingming Zhu; Fen Zhao; Zhenxiang Li; Jinming Yu
Immune checkpoint inhibitors (ICIs), represented by anti-CTLA-4 or anti-PD-1/anti-PD-L1 pathway antibodies, have led to a revolution in cancer treatment modalities. ICIs have unique clinical benefits, such as effectiveness against a broad range of tumor types, strong overall impact on survival, and persistent responses after the cessation of therapy. However, only a subset of patients responds to these therapies, and a small proportion of patients even experience rapid progression or an increased risk of death. Therefore, it is imperative to optimize patient selection for treatment. This review focuses on the mechanisms of tumor escape from immune surveillance, the composition and activity of a preexisting immune infiltrate, the degree of tumor foreignness (as reflected by the mutational burden, expression of viral genes, and driver gene mutations), and host factors (including peripheral blood biomarkers, genetic polymorphisms, and gut microbiome) to summarize current evidence on the biomarkers of responses to ICIs and explore the future prospects in this field.
Cancer Immunology, Immunotherapy | 2017
Yingming Zhu; Minghuan Li; Cong Bo; Xuemei Liu; Jianbo Zhang; Zhenxiang Li; Fen Zhao; Li Kong; Jinming Yu
International Journal of Radiation Oncology Biology Physics | 2017
Yingming Zhu; M. Li; Cong Bo; Xiangfa Liu; Jiandong Zhang; Zhenxiang Li; Fen Zhao; Li Kong; J. Yu
Journal of Cancer Research and Clinical Oncology | 2018
Yingming Zhu; Ke Tang; Fen Zhao; Yuanwei Zang; Xiaodong Wang; Zhenxiang Li; Xindong Sun; Jinming Yu
Journal of Clinical Oncology | 2017
Yingming Zhu; Jinming Yu; Minghuan Li
Journal of Clinical Oncology | 2017
Yingming Zhu; Yuanwei Zang; Minghuan Li; J. Yu
Journal of Clinical Oncology | 2017
Yingming Zhu; Minghuan Li; Jinming Yu
International Journal of Radiation Oncology Biology Physics | 2017
Yingming Zhu; M. Li; Dianbin Mu; Li Kong; Jiandong Zhang; Fen Zhao; Zhenxiang Li; Xiangfa Liu; Cong Bo; J. Yu